NA
BEAM icon

NewEdge Advisors’s Beam Therapeutics BEAM Stock Holding History

NewEdge Advisors’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.98K Hold
335
– – ﹤0.01% 3455
2025
Q4 		$9.29K Sell
335
-286
-46% -$7.3K ﹤0.01% 3488
2025
Q3 		$15.1K Hold
621
– – ﹤0.01% 3214
2025
Q2 		$10.6K Sell
621
-100
-14% -$1.74K ﹤0.01% 3200
2025
Q1 		$14.1K Buy
721
+487
+208% +$12.8K ﹤0.01% 2979
2024
Q4 		$5.8K Sell
234
-165
-41% -$4.21K ﹤0.01% 3191
2024
Q3 		$9.78K Hold
399
– – ﹤0.01% 2947
2024
Q2 		$9.35K Sell
399
-43
-10% -$1.06K ﹤0.01% 2877
2024
Q1 		$14.6K Buy
442
+43
+11% +$1.34K ﹤0.01% 2738
2023
Q4 		$10.9K Sell
399
-4
-1% -$99 ﹤0.01% 2811
2023
Q3 		$9.69K Hold
403
– – ﹤0.01% 2585
2023
Q2 		$12.9K Sell
403
-667
-62% -$21.6K ﹤0.01% 2530
2023
Q1 		$32.8K Sell
1,070
-327
-23% -$12.9K ﹤0.01% 2170
2022
Q4 		$16.6K Buy
+1,397
New +$62.6K ﹤0.01% 2190

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NewEdge Advisors's BEAM Position: Q1 2026 in Review

NewEdge Advisors held its Beam Therapeutics (BEAM) position steady in Q1 2026 at 335 shares worth $7.98K. The position accounts for ﹤0.01% of the portfolio, ranked #3455.

NewEdge Advisors first reported a position in BEAM in Q4 2022 and has held it in 14 quarters since. The position peaked at $32.8K in Q1 2023. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • NewEdge Advisors held 335 shares of Beam Therapeutics worth $7.98K as of Q1 2026.
  • NewEdge Advisors left its Beam Therapeutics share count unchanged in Q1 2026.
  • Beam Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q1 2026, its #3455 holding.
  • NewEdge Advisors first reported a position in Beam Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • NewEdge Advisors's Beam Therapeutics position peaked at $32.8K in Q1 2023.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on NewEdge Advisors's 13F filing for Q1 2026, filed 18 May 2026.